In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
T cells and enhances immunotherapy-induced tumor regression in mice. These investigations yield insight into aPD-1 target engagement in vivo and identify specific Fc/FcγR interactions that can be modulated to improve checkpoint blockade therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Real-time in vivo imaging allows one to identify not only primary targets of immunotherapeutics (drug pharmacokinetics) (Arlauckas et al., 2017) but also how the tumor microenvironment responds to treatment (drug pharmacody namics).”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Arlauckas et al., 2017
In the citing paper
“Most recently, a study revealed another unexpected resistance mechanism to anti-PD-1 therapy in mice whereby tumor-associated macrophages removed the therapeutic antibody from the surface of the T cells in vivo, thus making them once again susceptible to inhibitory signaling through the receptor.”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [114]
In the citing paper
“This phenomenon could be partially overcome by administration of Fc-receptor blocking agents prior to treatment (114).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationOncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Cited by
Items 101–200 of 673
Martínez-Usatorre, A., Kadioglu, E., Boivin, G., Cianciaruso, C., Guichard, A., Torchia, B., Zangger, N., Nassiri, S., Keklikoglou, I., Schmittnaegel, M., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd1616 · Cited by 119
Dong, X., Yang, A., Bai, Y., Kong, D., & Lv, F. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119659 · Cited by 105
Nakazawa, T., Natsume, A., Nishimura, F., Morimoto, T., Matsuda, R., Nakamura, M., Yamada, S., Nakagawa, I., Motoyama, Y., Park, Y.-S., et al. (2020) · Cells · doi:10.3390/cells9040998 · Cited by 103
“reported that although anti-PD-1 antibodies effectively bind PD-1 on CD8-positive tumor-infiltrating T cells, these antibodies are only effective early after treatment, as they are later captured from the T-cell surface by tumor-associated macrophages [26].”
BackgroundNimmerjahn, F., Vidarsson, G., & Cragg, M. S. (2023) · Nature Immunology · doi:10.1038/s41590-023-01544-8 · Cited by 112
The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer
Cai, J., Qi, Q., Qian, X., Han, J. G., Zhu, X., Zhang, Q., & Xia, R. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02879-2 · Cited by 107
Deshpande, R. P., Sharma, S., & Watabe, K. (2020) · Cancers · doi:10.3390/cancers12102983 · Cited by 108
“Blockade of FcγRs enhanced the effect of immunotherapy by prolonging the binding between PD-1 antibody and CD-8 T cells [26].”
BackgroundTumor-associated macrophages: a short compendium
Prenen, H., & Mazzone, M. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2997-3 · Cited by 108
Orecchioni, S., Talarico, G., Labanca, V., Calleri, A., Mancuso, P., & Bertolini, F. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0076-z · Cited by 98
Cas9-edited immune checkpoint blockade PD-1 DNA polyaptamer hydrogel for cancer immunotherapy
Lee, J., Le, Q., Yang, G., & Oh, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119359 · Cited by 102
Miller, M. A., Mikula, H., Luthria, G., Li, R., Kronister, S., Prytyskach, M., Kohler, R. H., Mitchison, T., & Weissleder, R. (2018) · ACS Nano · doi:10.1021/acsnano.8b07954 · Cited by 97
Self-citationMetabolic interplay: tumor macrophages and regulatory T cells
Vilbois, S., Xu, Y., & Ho, P. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.11.007 · Cited by 108
The Multifaceted Roles of Macrophages in NAFLD Pathogenesis
Vonderlin, J., Chavakis, T., Sieweke, M., & Tacke, F. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.03.002 · Cited by 96
Bartelink, I. H., Jones, E. F., Shahidi‐Latham, S. K., Lee, P. R. E., Zheng, Y., Vicini, P., van ‘t Veer, L., Wolf, D., Iagaru, A., Kroetz, D. L., et al. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1211 · Cited by 96
“Therefore, the interest for TAMs in oncology is not limited to their role in suppressing antitumor immune therapy response, but extends to the fact that they may limit drug target binding through macrophage- directed drug clearance(64) especially of lipophilic drugs,(27) or by removal of immunotherapeutic antibodies f…”
BackgroundRodell, C. B., Ahmed, M. S., Garris, C. S., Pittet, M. J., & Weissleder, R. (2019) · Theranostics · doi:10.7150/thno.35434 · Cited by 93
Self-citationFcγ receptors and immunomodulatory antibodies in cancer
Gálvez‐Cancino, F., Simpson, A. P., Costoya, C., Matos, I. G., Qian, D., Peggs, K. S., Litchfield, K., & Quezada, S. A. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00637-8 · Cited by 104
“Several studies have suggested a negative impact of FcγR binding to anti-PD1 hIgG4, including capturing of PD1 antibodies by FcγR-expressing TAMs 140 and depletion of the PD1 hi tumour-reactive T cells that have the capacity to kill tumour cells 139 .”
Liu, B., Guo, H., Xu, J., Qin, T., Guo, Q., Gu, N., Zhang, D., Qian, W., Dai, J., Hou, S., et al. (2018) · mAbs · doi:10.1080/19420862.2017.1409319 · Cited by 94
“Although SIRPa-CD47 interaction may serve as a primary regulatory “don’t eat me” signal on macrophages, recent work had demonstrated that PD-1 overexpression in mouse and human tumor-associated macrophages (TAMs) inhibited phagocytosis of cancer cell by TAMs.19,20 Furthermore, MYC oncogene was found to induce the expr…”
BackgroundHo, W. W., Gomes-Santos, I. L., Aoki, S., Datta, M., Kawaguchi, K., Talele, N. P., Roberge, S., Ren, J. P., Liu, H., Chen, I. X., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2105323118 · Cited by 102
Self-citationImaging of anticancer drug action in single cells
Miller, M. A., & Weissleder, R. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.41 · Cited by 92
Self-citationKather, J. N., & Halama, N. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0441-6 · Cited by 101
“Recent data suggest that some resistance mechanisms might be mediated by macrophages.(72) In a broader approach, chemotherapy was combined with immunomodulation in the GOLFIG trials, in which a combination of gemcitabine, oxaliplatin, folinic acid, fluorouracil, interleukin (IL)-2 and granulocyte-macrophage colony-sti…”
BackgroundBiology and therapeutic targeting of tumour‐associated macrophages
Beltraminelli, T., & De Palma, M. (2020) · The Journal of Pathology · doi:10.1002/path.5403 · Cited by 86
Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy
Siwicki, M., Gort-Freitas, N. A., Messemaker, M., Bill, R., Gungabeesoon, J., Engblom, C., Zilionis, R., Garris, C., Gerhard, G. M., Kohl, A., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abi7083 · Cited by 88
Self-citationTong, N., He, Z., Ma, Y., Wang, Z., Huang, Z., Cao, H., Xu, L., Zou, Y., Wang, W., Yi, C., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.706286 · Cited by 99
Chamseddine, A. N., Assi, T., Mir, O., & Chouaïb, S. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107986 · Cited by 94
Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
Chen, J., Yang, J. A., Wang, W., Guo, D., Zhang, C., Wang, S., Lu, X., Huang, X., Wang, P., Zhang, G., et al. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-022-00926-6 · Cited by 94
“Macrophages were also reported to capture αPD-1 from the T-cell surface via the Fcγ receptor [30].”
BackgroundIn vivo NIR-II structured-illumination light-sheet microscopy
Wang, F., Ma, Z., Zhong, Y., Salazar, F., Xu, C., Ren, F., Qu, L., Wu, A. M., & Dai, H. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2023888118 · Cited by 85
“Previous intravital imaging modalities included confocal microscopy (73), two-photon microscopy (74), or multiphoton microscopy (75), all of which have been used to investigate responses of the immune system to immunotherapy.”
BackgroundMayer, A. T., & Gambhir, S. S. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.185967 · Cited by 86
“(114); macrophage is in red, T cell in blue, and PD-1 in yellow) (G); MRI of dendritic cells labeled with superparamagnetic iron oxide (adapted from de Vries et al.”
BackgroundMyeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
Peranzoni, E., Ingangi, V., Masetto, E., Pinton, L., & Marigo, I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01590 · Cited by 86
“Besides, the use of FcγRIIb/III blocking antibodies prior to anti-PD-1 improved its anti-tumor efficacy in mice (130).”
MethodImmune Therapy Resistance and Immune Escape of Tumors
Seliger, B., & Massa, C. (2021) · Cancers · doi:10.3390/cancers13030551 · Cited by 86
“In addition, they can also mediate a “direct” resistance to iCPI therapy by removing antibodies from the surface of nearby effector cells [87].”
BackgroundWang, B., Yin, H., Zhang, Y., Zhao, Q., Wang, H., Wei, J., Meng, L., Xin, Y., & Jiang, X. M. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01073-9 · Cited by 92
Bridging live-cell imaging and next-generation cancer treatment
Alieva, M., Wezenaar, A. K. L., Wehrens, E. J., & Rios, A. C. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00610-5 · Cited by 100
“This approach is especially well suited to study the response of cancer cells, the tumour microenvironment 22 including immune cells 135 , vasculature 22,138 and both distant and surrounding normal tissues 59,60 to systemic drug treatment.”
BackgroundMethodImmune evasion mechanisms in acute myeloid leukemia: A focus on immune checkpoint pathways
Taghiloo, S., & Asgarian‐Omran, H. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103164 · Cited by 93
Nakajima, T. E., Kadowaki, S., Minashi, K., Nishina, T., Yamanaka, T., Hayashi, Y., Izawa, N., Muro, K., Hironaka, S., Kajiwara, T., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3559 · Cited by 89
Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
Xiao, Q., Nobre, A., Piñeiro, P., Berciano‐Guerrero, M., Alba, E., Cobo, M., Lauschke, V. M., & Barragán, I. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010286 · Cited by 84
Induction of breast cancer stem cells by M1 macrophages through Lin-28B-let-7-HMGA2 axis
Guo, L., Cheng, X., Chen, H., Chen, C., Xie, S., Zhao, M., Liu, D., Deng, Q., Liu, Y., Wang, X., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.03.032 · Cited by 82
Belgiovine, C., Digifico, E., Anfray, C., Ummarino, A., & Torres, F. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103226 · Cited by 90
“For example, TAMs overexpress PD-L1 that reduces the efficacy of anti PD-1 therapies [57], by sequestering anti-PD-1 antibodies and also by unspecific binding [58].”
BackgroundVlahopoulos, S. (2017) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2017.0029 · Cited by 90
Determinants of Ligand-Functionalized DNA Nanostructure–Cell Interactions
Cremers, G. A. O., Rosier, B. J. H. M., Meijs, A., Tito, N. B., van Duijnhoven, S. M. J., van Eenennaam, H., Albertazzi, L., & de Greef, T. F. A. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c02298 · Cited by 84
Zhou, B., Gao, Y., Zhang, P., & Chu, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.693609 · Cited by 91
“Intriguingly, TAMs can also steal anti-PD-1 mAbs to alleviate efficacy (99).”
BackgroundTargeted Repolarization of Tumor‐Associated Macrophages via Imidazoquinoline‐Linked Nanobodies
Bolli, E., Scherger, M., Arnouk, S. M., Antunes, A. R. P., Straßburger, D., Urschbach, M., Stickdorn, J., Vlaminck, K. D., Movahedi, K., Räder, H. J., et al. (2021) · Advanced Science · doi:10.1002/advs.202004574 · Cited by 80
Ceci, C., Atzori, M. G., Lacal, P. M., & Graziani, G. (2020) · Cancers · doi:10.3390/cancers12113401 · Cited by 85
“Indeed, in vivo imaging studies in different murine cancer models demonstrated that after intraperitoneal administration, an anti-PD-1 mAb co-localized with tumor-infiltrating T-cells at early time points, being then captured by TAMs [57].”
BackgroundHu, C., Zhao, L., Liu, W., Fan, S., Liu, J., Liu, Y., Liu, X., Shu, L., Liu, X., Liu, P., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003773 · Cited by 89
Lurje, I., Werner, W., Mohr, R. U., Roderburg, C., Tacke, F., & Hammerich, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.650486 · Cited by 85
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
Truxová, I., Cibula, D., Špíšek, R., & Fucikova, J. P. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005968 · Cited by 83
Recording the wild lives of immune cells
Pittet, M. J., Garris, C., Arlauckas, S. P., & Weissleder, R. (2018) · Science Immunology · doi:10.1126/sciimmunol.aaq0491 · Cited by 77
Self-citationPrediction of anti-cancer nanotherapy efficacy by imaging
Miller, M. A., Arlauckas, S., & Weissleder, R. (2017) · Nanotheranostics · doi:10.7150/ntno.20564 · Cited by 74
“Because late FMX-MRI can predict TAM abundance, it could find application in predicting and monitoring the activity of TAM-targeted therapies including CSF1R inhibitors [104], anti-PD-L1 checkpoint blockade therapy [105], and antibody therapies that are influenced by Fcγ receptor activity on TAM [59].”
BackgroundSelf-citationTrial watch: immune checkpoint blockers for cancer therapy
Vanpouille-Box, C., Lhuillier, C., Bezu, L., Aranda, F., Yamazaki, T., Kepp, O., Fucikova, J., Spisek, R., Demaria, S., Formenti, S. C., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1373237 · Cited by 73
Rupp, T., Genest, L., Babin, D., Legrand, C., Hunault, M., Froget, G., & Castagné, V. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101405 · Cited by 77
“Resistance mechanism to anti-PD-1 has been recently proposed to be associated with tumor-associated macrophages that could bypass the targeting of T cells [73] or with mutation in key signaling pathways such as JAK1/2 kinases inducing IFN γ lack of response [74,75].”
Dosta, P., Puigmal, N., Cryer, A. M., Rodríguez, A. L., Scott, E., Weissleder, R., Miller, M. A., & Artzi, N. (2022) · Theranostics · doi:10.7150/thno.73966 · Cited by 77
“Mus musculus skin melanoma (B16-F10 from ATCC) and colon carcinoma (H2B-mApple MC38, developed and described previously [47], were maintained in Dulbecco’s minimum essential medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS), 100 U/mL penicillin and 100 μg/mL streptomycin, 2 mM L-glutamine.”
InfluentialSelf-citationBiomarkers in Precision Cancer Immunotherapy: Promise and Challenges
McKean, W. B., Moser, J. C., Rimm, D. L., & Hu‐Lieskovan, S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280571 · Cited by 79
Pilanc, P., Wojnicki, K., Roura, A.-J., Cyranowski, S., Ellert‐Miklaszewska, A., Ochocka, N., Gielniewski, B., Grzybowski, M. M., Błaszczyk, R., Stańczak, P. S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703465 · Cited by 76
Diversity of immune checkpoints in cancer immunotherapy
Guo, Z., Zhang, R., Yang, A., & Zheng, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1121285 · Cited by 83
Zheng, P., He, J., Fu, Y., Yang, Y., Li, S., Duan, B., Yang, Y., Hu, Y., Yang, Z., Wang, M., et al. (2024) · ACS Nano · doi:10.1021/acsnano.3c06987 · Cited by 78
Targeting antigen-presenting cells by anti–PD-1 nanoparticles augments antitumor immunity
Ordikhani, F., Uehara, M., Kasinath, V., Dai, L., Eskandari, S. K., Bahmani, B., Yonar, M., Azzi, J. R., Haik, Y., Sage, P. T., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122700 · Cited by 72
“Discussion Immune checkpoint blockade with anti–PD-1 agents has demonstrated impressive benefits in the treatment of several cancers (33).”
BackgroundPorta, C., Sica, A., & Riboldi, E. (2018) · The FEBS Journal · doi:10.1111/febs.14288 · Cited by 69
Cotechini, T., Atallah, A., & Grossman, A. (2021) · Cells · doi:10.3390/cells10040960 · Cited by 82
The role of the innate immune system in the development and treatment of hepatocellular carcinoma
Roderburg, C., Wree, A., Demir, M., Schmelzle, M., & Tacke, F. (2020) · Hepatic Oncology · doi:10.2217/hep-2019-0007 · Cited by 69
“Moreover, macrophages, neutrophils and other immune cells of the innate arm were suggested to be involved in mediating resistance against checkpoint inhibitors [31].”
BackgroundLi, Y., Wu, H. C., Ji, B., Qian, W., Xia, S., Wang, L., Xu, Y., Chen, J., Yang, L. P. H., & Mao, H. Z. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00368 · Cited by 75
Tumor-Mediated Neutrophil Polarization and Therapeutic Implications
Raftopoulou, S., Valadez-Cosmes, P., Mihalič, Z. N., Schicho, R., & Kargl, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063218 · Cited by 75
Baicalein Potentiated M1 Macrophage Polarization in Cancer Through Targeting PI3Kγ/ NF-κB Signaling
He, S., Wang, S., Liu, S., Li, Z., Liu, X., & Wu, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.743837 · Cited by 67
“Selectively depletion of TAMs and reprogramming immunosuppressive M2-like TAMs to antitumor M1 phenotypes has been explored for anti-tumor therapies (Arlauckas et al., 2017; Cassetta and Pollard, 2018).”
BackgroundExcellent response to chemotherapy post immunotherapy
Dwary, A. D., Master, S. R., Patel, A., Cole, C., Mansour, R. P., Mills, G. M., Koshy, N. V., Peddi, P., Burton, G. V., Hammoud, D. A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20030 · Cited by 67
From therapeutic antibodies to immune complex vaccines
Wang, X., Wang, B., & Wen, Y. (2019) · npj Vaccines · doi:10.1038/s41541-018-0095-z · Cited by 76
Kato, S., Okamura, R., Kumaki, Y., Ikeda, S., Nikanjam, M., Eskander, R. N., Goodman, A. M., Lee, S., Glenn, S. T., Dressman, D. C., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1708065 · Cited by 70
Visualizing vasculature and its response to therapy in the tumor microenvironment
Lin, Q., Choyke, P. L., & Sato, N. (2023) · Theranostics · doi:10.7150/thno.84947 · Cited by 76
“A possible way to overcome this problem has been reported based on an interesting observation in a dorsal window chamber model by Arlauckas SP and collaborators [177].”
MethodGlucose Metabolism: The Metabolic Signature of Tumor Associated Macrophage
Zhang, Q., Wang, J., Yadav, D. K., Bai, X., & Liang, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.702580 · Cited by 63
“org 4 glycolysis in TAMs and have recognized more subtypes of TAMs in cancer like CD68+ TAM in non-small cell lung cancer (NSCLC) (74), CD169+ macrophages in PADC (75, 76), CD163+ macrophages in epithelial ovarian cancer (77), and PD-1+ macrophages in primary mouse and human cancer (78).”
BackgroundDammeijer, F. F., Lau, S. P., van Eijck, C. H. J., van der Burg, S. H., & Aerts, J. G. J. V. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.011 · Cited by 75
Tricarboxylic acid cycle metabolites in the control of macrophage activation and effector phenotypes
Noe, J. T., & Mitchell, R. A. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.3ru1218-496r · Cited by 70
Recent success and limitations of immune checkpoint inhibitors for cancer: A lesson from melanoma
Ottaviano, M., De Placido, S., & Ascierto, P. A. (2019) · Virchows Archiv · doi:10.1007/s00428-019-02538-4 · Cited by 57
Camelliti, S., Noci, V. L., Bianchi, F., Moscheni, C., Arnaboldi, F., Gagliano, N., Balsari, A., Garassino, M. C., Tagliabue, E., Sfondrini, L., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01721-9 · Cited by 68
“Indeed, nivolumab and pembrolizumab, anti-PD-1 antibodies, are IgG4, an isotype considered immunologically inert but that still retains the ability to bind FcγRI and FcγRIIb, activating and inhibitory FcRs, respectively [90–92].”
BackgroundInfluentialCurrent status of immunotherapy for advanced gastric cancer
Kawazoe, A., Shitara, K., Boku, N., Yoshikawa, T., & Terashima, M. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa202 · Cited by 67
Acúrcio, R. C., Pozzi, S., Carreira, B., Pojo, M., Gómez-Cebrián, N., Casimiro, S., Fernandes, A. M. A., Barateiro, A. P., Farricha, V., do Brito, J. S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004695 · Cited by 63
Improving nanotherapy delivery and action through image-guided systems pharmacology
Ng, T. S. C., Garlin, M. A., Weissleder, R., & Miller, M. A. (2020) · Theranostics · doi:10.7150/thno.37215 · Cited by 60
“Nanomaterials can be fluorescently labeled for kinetic tracking [5, 30, 34], and combined with alternatively fluorescently labeled drug payloads to differentiate between the kinetics of the nano carrier and their encapsulated therapeutic [31, 35, 36].”
BackgroundSelf-citationLi, C., Qiu, Q., Gao, X., Yan, X., Fan, C., Luo, X., Liu, X., Wang, S., Lai, X., Song, Y., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.06.027 · Cited by 60
Immunotherapy in Breast Cancer: When, How, and What Challenges?
Henriques, B., Mendes, F., & Martins, D. F. (2021) · Biomedicines · doi:10.3390/biomedicines9111687 · Cited by 72
Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens
Song, M., Chen, X., Wang, L., & Zhang, Y. (2018) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2018.02.01 · Cited by 63
Seo, H., Kim, B. S., Bae, E., Min, B. S., Han, Y. D., Shin, S. J., & Kang, C. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0708 · Cited by 62
“These authors also show that PD-1/PD-L1 blockade inhibits tumor growth in various mouse tumor models by enhancing the phagocytosis of TAMs (42, 43).”
BackgroundFalvo, P., Orecchioni, S., Hillje, R., Raveane, A., Mancuso, P., Camisaschi, C., Luzi, L., Pelicci, P. G., & Bertolini, F. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1818 · Cited by 65
“In this context, it is noteworthy that myeloid cells, and in particular macrophages, are known to mediate tumor resistance to CIs (37, 38).”
BackgroundPan, Y., Fu, Y., Zeng, Y., Liu, X., Peng, Y., Hu, C., Deng, C., Qiu, Z., Zou, J. P., Liu, Y., et al. (2022) · Biomarker Research · doi:10.1186/s40364-022-00355-7 · Cited by 60
“However, TAM can “rob” anti-PD-1 antibodies from the surface of CD8+ positive T cells, swallow them into the body, and make them ineffective [74].”
BackgroundTreatment of NSCLC after chemoimmunotherapy — are we making headway?
Reck, M., Frost, N., Peters, S., Fox, B. A., Ferrara, R., Savai, R., & Barlési, F. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01061-7 · Cited by 70
“Furthermore, TAMs positive for the inhibitory receptor FcγRIIb might undergo protumour reprogramming upon interactions with the Fc domain of anti-PD-1 antibodies and can even capture these antibodies and render them ineffective 189,190 .”
Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells
Robbins, Y. L., Greene, S., Friedman, J., Clavijo, P. E., Waes, C. V., Fabian, K. P., Padget, M. R., Sater, H. A., Lee, J. H., Soon‐Shiong, P., et al. (2020) · eLife · doi:10.7554/elife.54854 · Cited by 58
Xie, X., Zhang, J., Zhongyuan, S., Liu, W., Hu, X., Qie, C., Chen, W., Wang, Y., Wang, L. L., Jiang, J., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.563044 · Cited by 59
“In addition, recent studies have shown that macrophages can disable immune checkpoint therapy by endocytosing anti-PD-L1 antibodies (28).”
BackgroundTargeting the Antibody Checkpoints to Enhance Cancer Immunotherapy–Focus on FcγRIIB
Teige, I., Mårtensson, L., & Frendéus, B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00481 · Cited by 59
“This demonstrates that FcγRs negatively regulate anti-PD-1 antibody efficacy.”
BackgroundInfluentialTargeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy
Sanctis, F. D., Adamo, A., Canè, S., & Ugel, S. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00965-1 · Cited by 58
“Furthermore, TAMs play a negative role in ICT such as by preventing cytotoxic T cells from reaching tumour cells [39] as well as by promoting antibody clearance activity through Fc-Fcγ receptor binding [40].”
BackgroundImmunoengineering with biomaterials for enhanced cancer immunotherapy
Xie, Y., Wei, L., & Tang, L. (2018) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1506 · Cited by 55
Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma
Veldman, J., Visser, L., van den Berg, A., & Diepstra, A. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101931 · Cited by 56
“Category Mechanism Literature T cell activation Lack of neoantigens [10-12,14,29-31] Impaired processing or presentation of neoantigens [13,15,32] T cell attraction Inhibition of T cell influx into the TME [16,17] Induction of T cell effector functions Mutations in immune effector signaling pathways [13,26] Upregulati…”
BackgroundThe Current Landscape of Antibody-based Therapies in Solid Malignancies
Shah, A., Rauth, S., Aithal, A., Kaur, S., Ganguly, K., Orzechowski, C., Varshney, G. C., Jain, M., & Batra, S. K. (2021) · Theranostics · doi:10.7150/thno.52614 · Cited by 49
“Inhibition of FcγR by blocking mAbs resulted in complete tumor rejection in all animals by prolonging the interaction time between anti-PD-1 mAbs and PD-1 expressing CD8+ T cells [71].”
BackgroundAllen, S. D., Liu, X., Jiang, J., Liao, Y., Chang, C. H., Nel, A. E., & Meng, H. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120635 · Cited by 56
Komohara, Y., Kurotaki, D., Tsukamoto, H., Miyasato, Y., Yano, H., Pan, C., Yamamoto, Y., & Fujiwara, Y. (2023) · Cancer Science · doi:10.1111/cas.15751 · Cited by 53
Natarajan, A., Patel, C. B., Habte, F. G., & Gambhir, S. S. (2018) · Scientific Reports · doi:10.1038/s41598-017-19123-x · Cited by 55
Tu, S., Xu, L., Qiu, J., Zhou, J., Wang, H., Hu, S., Yao, Y., Wang, Y., Deng, Y., Zhou, Y., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.650105 · Cited by 57
“However, anti-PD-1 antibodies were found to be recaptured by TAM/Ms via FcgR, which indicates another mechanism by which TAM/Ms help maintain an immunosuppressive microenvironment in immune checkpoint therapy (102).”
BackgroundSafety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors
Chen, C.-L., Pan, Q., Weng, D., Xie, C.-M., Zhao, J.-J., Chen, M.-S., Peng, R.-Q., Li, D., Wang, Y., Tang, Y., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1417721 · Cited by 52
“, myeloid cells or macrophages) in the tumor bed.(25) We”
BackgroundAcquired resistance to cancer immunotherapy
Draghi, A., Chamberlain, C. A., Furness, A. J. S., & Donia, M. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0692-y · Cited by 52
Li, F., Ulrich, M. L., Shih, V. F.-S., Cochran, J. H., Hunter, J. H., Westendorf, L., Neale, J. R., & Benjamin, D. R. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0977 · Cited by 57
“Interestingly, several studies have demonstrated that Fc-FcγR interaction with tumor-associated macrophages and other antigenpresenting cells may influence the antitumor efficacy of antibody and ADCs in animal models (25-27).”
Tumor Immunosurveillance and Immunotherapies: A Fresh Look from Intravital Imaging
Boulch, M., Grandjean, C. L., Cazaux, M., & Bousso, P. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.09.002 · Cited by 53
The expanding landscape of inflammatory cells affecting cancer therapy
Weissleder, R., & Pittet, M. J. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0524-y · Cited by 55
Self-citationSong, Y., Gao, Q., Zhang, H., Fan, L., Zhou, J., Zou, D., Li, W., Yang, H., Liu, T., Wang, Q., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2023 · Cited by 55
“It was hence hypothesized that tislelizumab may induce deeper responses and longer duration of response (DOR), especially in tumor types with high macrophage in fi ltration, such as cHL (18, 19).”
Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies
Ngiow, S. F., & Young, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01633 · Cited by 54
“More recently, it has been shown that TAMs (CD11b MHC-II) are capable of stripping anti-PD-1 bound to PD-1 T cells by binding to the antibody Fc domain, abrogating the anti-tumor activity of this immune checkpoint inhibitor (17).”
BackgroundChen, Y., Zhang, C., Peng, Z., Qi, C., Gong, J., Zhang, X., Li, J., & Shen, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.589022 · Cited by 53
Macrophage and monocyte subsets as new therapeutic targets in cancer immunotherapy
Fendl, B., Berghoff, A. S., Preusser, M., & Maier, B. (2023) · ESMO Open · doi:10.1016/j.esmoop.2022.100776 · Cited by 54
“showed that PD-1 TAMs can heist T cell-bound anti-PD-1 antibodies, which can be prevented by blockage of Fcg receptors on TAMs, resulting in enhanced tumor regression.(59) These findings highlight the participation of Fc/FcgR interactions in the context of therapy efficacy.”
BackgroundZanganeh, S., Spitler, R., Hütter, G., Ho, J. Q., Pauliah, M., & Mahmoudi, M. (2017) · Immunotherapy · doi:10.2217/imt-2017-0041 · Cited by 49
Tumor-Associated Macrophages: Combination of Therapies, the Approach to Improve Cancer Treatment
Moeini, P., & Niedźwiedzka‐Rystwej, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137239 · Cited by 54
Metadata
- Authors
- Arlauckas, S. P., Garris, C. S., Kohler, R. H., Kitaoka, M., Cuccarese, M. F., Yang, K. S., Miller, M. A., Carlson, J. C., Freeman, G. J., Anthony, R. M., Weissleder, R., & Pittet, M. J.
- Affiliations
- Harvard University (US)
- Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge Street, CPZN 5206, Boston, MA 02114, USA.
- Massachusetts General Hospital (US)
- Corresponding author
- Arlauckas, Sean P.
- Garris, Christopher S.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-05-10
- Volume
- 9
- Issue
- 389
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5734617
- OpenAlex
- W2612649234
- Cited by
- 669
- References
- 55
- Citations by year
- 2026: 50 · 2025: 57 · 2024: 76 · 2023: 75 · 2022: 84 · 2021: 98 · 2020: 87 · 2019: 62 · 2018: 50 · 2017: 29
- FWCI
- 27.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion)
- PubMed Central (acceptedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion)
- Funders
- National Institutes of Health (award301192, 5P50CA086355, award301190, R01AI084880, award301193, R21CA190344, award301191, U54-CA151884)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor-associated macrophages, anti-PD-1 therapy, immune checkpoint inhibitor resistance, T cell activation, tumor regression, in vivo imaging, target engagement
- MeSH terms
- Animals, Antibodies, Monoclonal, Cells, Cultured, Humans, Immunotherapy, Mice, Inbred C57BL, Receptors, IgG, CD8-Positive T-Lymphocytes, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.